About Walvax Biotechnology Company

The company was founded in 2001 and is a high-tech biopharmaceutical enterprise specializing in biotechnological drugs such as human vaccines, integrating R&D, production and sales. In 2010, Watson Biotech was successfully listed on the Shenzhen Stock Exchange, becoming the first company in Yunnan Province to be listed on the China GEM. Watson Biotech always adheres to the main theme of “making people born healthy”, incorporates social responsibility into the company's development strategy and management, takes strict adherence to product quality and safety as its mission, never forgets its original intention, keeps up with the times, and strives to create outstanding achievements worthy of society and the times. The company is a high-tech biopharmaceutical enterprise specializing in R&D, production and sales of biotechnological drugs such as human vaccines, and is in a leading position in the biotechnological drug segment represented by novel vaccines. The main autonomous vaccine products produced and sold by the company are: 13-valent pneumococcal conjugate vaccine (cillin bottle type and pre-encapsulated type), bivalent HPV vaccine (cyrine bottle type and prefilled type), 23-valent pneumococcal polysaccharide vaccine (cyrine bottle type and pre-encapsulated type), group A group C meningococcal polysaccharide conjugate vaccine, ACYW135 group meningococcal polysaccharide vaccine, group A group C meningococcal polysaccharide vaccine, group A group C meningococcal polysaccharide vaccine, group A group C meningococcal polysaccharide vaccine, group A group C meningococcal polysaccharide vaccine, group A group C meningococcal polysaccharide vaccine, group A group C meningococcal polysaccharide vaccine Cytomegalovirus combination vaccine. Corporate honors: National Accredited Enterprise Technology Center, High-tech Enterprise, National High-tech Industrialization Demonstration Project, 70 years since the establishment of New China, the most growing listed company in biomedicine in the 2021 Chinese Listed Company Reputation List, won the honorary title of “Kunming Industrial Development Contribution Award” and “China Pharmaceutical Independent Innovation Pioneer Enterprise” and the title of “National Technological Innovation Demonstration Enterprise” jointly recognized and awarded by the Ministry of Industry and Information Technology and the Ministry of Finance. The company's “Development and Major Industrialization of Novel Pneumococcal Vaccine Series” project won the first prize of the Yunnan Science and Technology Progress Award, etc.